The Arkansas approach to therapy of patients with multiple myeloma
- 31 December 2007
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 20 (4), 761-781
- https://doi.org/10.1016/j.beha.2007.09.005
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- High-dose melphalan-based autotransplants for multiple myelomaCancer, 2008
- High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisBlood, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With MyelomaJournal of Clinical Oncology, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myelomaBritish Journal of Haematology, 1996
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969